

Evonik Cyro Launches CYREX® Protect For Antimicrobial Medical Devices CYREX® Toughness Now Available With Antimicrobial Properties

PARSIPPANY, N.J., May 24, 2012 – Evonik Cyro today launched [CYREX® Protect](#), an opaque acrylic–polycarbonate alloy for antimicrobial medical device designs, at the [Medical Design & Manufacturing East Trade Show](#) in Philadelphia, Pa.

Antimicrobial properties are built into CYREX® Protect during manufacturing, which eliminates a surface coating that can scratch or wear off. CYREX® Protect provides antimicrobial capabilities, as tested by the JIS Z 2801 protocol, against a variety of microorganisms found in healthcare facilities. In addition to its antimicrobial capability, CYREX® Protect delivers outstanding strength and toughness with a notched Izod impact test value of 12 ft–lb/in.

The product is designed to meet U.S. Food and Drug Administration (FDA) regulated Class I or Class II medical devices covered by 510(k) PMN submission and is well–suited for Luer connectors, spikes, Y–sites, check valves and filter housings.

“Evonik Cyro is constantly seeking ways to create products that meet the needs of our customers and anticipate their future demands,” said Wade Schneider, Medical Market Segment Manager at Evonik Cyro. “In recent years, healthcare facilities have been concerned about secondary device–related infections and the costs associated with them. Now, medical devices made from CYREX® Protect can help reduce or prevent device–related infections.”

CYREX® Protect has demonstrated efficacy of >4 as tested following JIS Z 2801 protocol against the following four microorganisms after both 24 hours and 96 hours of exposure: staphylococcus aureus, the common cause of staph infections; pseudomonas aeruginosa, a microorganism naturally resistant to penicillin; staphylococcus epidermidis, which increases the risk of infection for those with weaker immune systems; and klebsiella pneumoniae, a respiratory patient risk.

CYREX® Protect is resistant to plasticizers found in flexible polyvinyl chloride (PVC). It can be sterilized with gamma, e–beam and EtO technologies.

CYREX® Protect polymer has passed Class VI United States Pharmacopoeia tests for determining the suitability of a plastic material intended for use in fabricating containers or accessories for parenteral preparations. CYREX® Protect alloy is not suitable for implantable devices. Users must undertake sufficient verification and testing to determine suitability for their own particular purpose.

For additional information about CYREX® Protect visit www.acrylite-polymers.com. To request a sample, call +1 800 631-5384.

For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (adjusted EBITDA) of about €2.8 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Cyro LLC nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

For more information, contact:

Gail Wood

Evonik Degussa Corporation

Tel: +1 973 929-8754

Email: gail.wood@evonik.com